Docoh
Loading...

MYGN Myriad Genetics

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

Company profile

Ticker
MYGN
Exchange
Website
CEO
R. Bryan Riggsbee
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
870494517

MYGN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 148.9M 148.9M 148.9M 148.9M 148.9M 148.9M
Cash burn (monthly) (positive/no burn) (positive/no burn) 16.53M 24.61M (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a 46.09M 68.61M n/a n/a
Cash remaining n/a n/a 102.81M 80.29M n/a n/a
Runway (months of cash) n/a n/a 6.2 3.3 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Jun 21 Spiegelman Daniel K Common Stock Sell Dispose S No Yes 30.5176 3,139 95.79K 23,129
3 Jun 21 Heinrich Dreismann Common Stock Grant Aquire A No No 0 12,848 0 83,527
3 Jun 21 Dennis Langer Common Stock Grant Aquire A No No 0 12,848 0 89,527
3 Jun 21 Lee Nisley Newcomer Common Stock Grant Aquire A No No 0 12,848 0 40,424
3 Jun 21 Spiegelman Daniel K Common Stock Grant Aquire A No No 0 12,848 0 26,268

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

99.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 194 187 +3.7%
Opened positions 37 25 +48.0%
Closed positions 30 26 +15.4%
Increased positions 53 58 -8.6%
Reduced positions 73 67 +9.0%
13F shares
Current Prev Q Change
Total value 3.51B 1.56B +125.8%
Total shares 76.77M 78.66M -2.4%
Total puts 83.4K 143.5K -41.9%
Total calls 122.8K 173.2K -29.1%
Total put/call ratio 0.7 0.8 -18.0%
Largest owners
Shares Value Change
BLK Blackrock 13.23M $402.85M +5.8%
Vanguard 8.62M $262.62M +4.0%
Earnest Partners 7.19M $218.79M +6.7%
STT State Street 4.03M $122.86M +8.6%
D. E. Shaw & Co 3.22M $63.59M 0.0%
Camber Capital Management 3M $91.35M -40.0%
BAC Bank Of America 2.75M $83.61M +5.7%
Dimensional Fund Advisors 2.73M $82.93M -1.1%
Partner Fund Management 2.72M $82.78M NEW
D. E. Shaw & Co. 2.66M $80.99M -17.3%
Largest transactions
Shares Bought/sold Change
Partner Fund Management 2.72M +2.72M NEW
Camber Capital Management 3M -2M -40.0%
MS Morgan Stanley 746.4K -1.48M -66.4%
Glenview Capital Management 2.57M -1.11M -30.2%
Wellington Management 878.93K +878.93K NEW
Norges Bank 0 -731.26K EXIT
BLK Blackrock 13.23M +727.96K +5.8%
D. E. Shaw & Co. 2.66M -555.74K -17.3%
IVZ Invesco 981.3K +478.59K +95.2%
Earnest Partners 7.19M +453.92K +6.7%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accurately, America, Autoimmune, behavior, capacity, cardiovascular, Castle, claim, clarification, combinatorial, Commonwealth, Conference, Delaware, Dermatology, diligently, disallowed, dollar, elevate, entertainment, established, expansion, explore, exploring, extension, fewer, formal, formally, found, founding, fully, Growth, immunoassay, inflammation, Intermountain, largest, leasehold, leave, Melanoma, misstatement, mix, multiplexed, myPath, newly, objectively, oncology, onset, play, primary, Psychotropic, purpose, RA, RBM, recovery, remediate, remediated, remediation, rheumatoid, robust, role, Score, select, sequencing, Society, somatic, specialty, submission, supervision, tumor, Zejula
Removed: adjustment, apply, applying, arrangement, authority, borrowed, breast, carried, categorized, classification, code, collected, commencement, comparative, concurrent, convertible, defined, determination, dismissed, Dividend, earliest, earned, efficiency, entry, fund, group, heading, highly, imposed, initially, jurisdiction, lack, large, liquid, model, October, Pathology, percent, perform, personal, pioneering, prospective, readily, realized, relationship, retrospective, scope, sheet, standing, subsequent, Supreme, upfront